2023 WCLC | Dr. Caicun Zhou Discusses Latest Results on EGFR exon20ins Mutation

2023 WCLC | Dr. Caicun Zhou Discusses Latest Results on EGFR exon20ins Mutation

The World Conference on Lung Cancer (WCLC), a significant academic exchange event in the global lung cancer field, was successfully held in Singapore from September 9 to 12, 2023. The conference revealed many important research findings, bringing about a new era of treatment in clinical practice. Among them, the EGFR Exon20 insertion mutation (EGFR exon20ins) as the third major EGFR mutation has garnered widespread attention. In recent years, novel treatments for this mutation have continuously emerged. At the WCLC, the phase 1b results of the FAVOUR study on the treatment of EGFR exon20ins-positive advanced non-small cell lung cancer (NSCLC) with furmonertinib were reported. " Oncology Frontier " had the privilege of interviewing Dr. Caicun Zhou, a leading figure in the field of lung cancer treatment at Shanghai Pulmonary Hospital and Tongji University School of Medicine. Dr. Zhou shared the latest treatments of EGFR exon20ins-positive NSCLC.
WCLC Interview | Dr. Clarissa Baldotto: Treatment strategies after failure of immunotherapy for lung cancer

WCLC Interview | Dr. Clarissa Baldotto: Treatment strategies after failure of immunotherapy for lung cancer

The 2023 World Conference of Lung Cancer (WCLC), organized by the International Association for the Study of Lung Cancer (IASLC), was grandly held in Singapore from September 9th to 12th. At the WCLC conference, Dr. Clarissa Baldotto, President of the Brazilian Group of Thoracic Oncology, was invited by “Oncology frontier” to talk about the treatment strategies for lung cancer after immunotherapy failure, as well as the current status and future development of oncology in Brazil.
Application of ADC in First-Line Treatment of NSCLC and Interpretation of Results from the EVOKE-02 Study

Application of ADC in First-Line Treatment of NSCLC and Interpretation of Results from the EVOKE-02 Study

The 24th World Conference on Lung Cancer (WCLC) was held from September 9 to 12, 2023, in Singapore, organized by the International Association for the Study of Lung Cancer (IASLC). During the oral presentation session on September 10, the EVOKE-02 study, exploring the first-line treatment of advanced non-small cell lung cancer (NSCLC) with the combination of sacituzumab govitecan (SG) and pembrolizumab, revealed its preliminary results. The study demonstrated an objective response rate (ORR) of 56% and a disease control rate (DCR) of 82% for stage IV NSCLC patients, laying the foundation for a new treatment strategy. " Oncology Frontier" invited Dr. Stephen V. Liu from Georgetown University Lombardi Comprehensive Cancer Center and Dr. Shun Lu from Shanghai Chest Hospital and Shanghai Jiao Tong University for a virtual dialogue to discuss the significance of the EVOKE-02 study and the future possibilities in NSCLC treatment.
Dr. Jie Jin:  the New JAK Inhibitor Jaktinib in the Treatment of Myelofibrosis (MF)

Dr. Jie Jin:  the New JAK Inhibitor Jaktinib in the Treatment of Myelofibrosis (MF)

The 28th European Hematology Association (EHA) Congress was held from June 8th to June 11th, 2023, in Frankfurt, Germany, in a hybrid format combining online and offline meetings. As the largest international conference in the field of European hematology, the EHA Congress covered a wide range of scientific topics, clinical and basic research, including both benign and malignant hematology, discussing the latest developments in the field. Regarding the treatment of Myelofibrosis (MF), several studies from Dr. Jie Jin's team at the First Affiliated Hospital of Zhejiang University (abstracts S212, P1201, and P1033) were selected for this congress. These studies focused on exploring the efficacy and safety of the new JAK inhibitor Jaktinib in the treatment of MF, attracting significant attention due to its clinical significance. In this regard, Oncology Frontier conducted an on-site interview with Professor Jin Jie and provided a brief explanation of this topic.